Ten genes, including AIMP2, AURKA, AURKB, CDC45, CDCA3, CKS1B, HMGB3, KPNA2, MCM5, and NCAPD2, which were downregulated following combination therapy, were found to be overexpressed in the melanoma TCGA cohort. This evidence concerns the gene KPNA2 and melanoma.